1. Ghali JK, Kay R, Shelton B et al. Contemporary аetiologies of left ventricular dysfunction and/or heart failure and their influence on prognosis. Circulation 1992; 86 (Suppl.): 2380.
2. Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208–25.
3. Sayen JJ, Sheldon WF, Peirce G, Kuo PT. Polarographic oxygen, the epicardial electrocardiogram and muscle contraction in experimental acute regional ischemia of the left ventricle. Circ Res 1958; 6: 779–98.
4. Tatooles CJ, Randall WC. Local ventricular bulding after acute coronary occlusion. Am J Physiol 1961; 201: 451–6.
5. Olivier V, Opie L. Effects of glucose and fatty acid on myocardial ischemia and arrhythmias. Lancet 1994; 343: 155–8.
6. Lopaschuk GD, Belke DD, Gamble J et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta 1994; 1213: 263–76.
7. King LM, Opie LH. Glucose and glycogen utilization in myocardial ischemia – change in metabolism and consequences for the myocyte. Mol Cell Biochem 1998; 180: 3–26.
8. Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from, where do they go to? J Mol Cell Cardiol 1991; 23: 1077–86.
9. Hansford RG, Cohen L. Relative importance of piruvate dehydrogenase interconversion and feedback inhibition in the effect of fatty acids on piruvate oxidation by rat heart mitochondria. Arch Biochem Biophys 1978; 191: 65–81.
10. Renaud JF. Internal pH, Na, and Ca regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drug Ther 1988; 1: 677–86.
11. Honore E, Adamantidis MM, Challice CE et al. Cardioprotection by calcium antagonists, pyridoxilate and trimetazidine. IRSC Med Sci 1986; 14: 938–9.
12. Roulet MJ, Garnier D. The anti-anginal drug, trimetazidine, potentiates the tension on hypoxic ductus arteriosus. INSERM 1984; 124: 481–8.
13. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148–51.
14. Passeron J. Clinical efficacy of trimetazidine in stable angina pectoris. Presse Med 1986; 15: 1775–8.
15. Dalla-Volta S, Maraglino G, Della-Valentina P et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990; 4: 853–60.
16. Терещенко С.Н., Акимова О.С., Коровина Е.А., Моисеев В.С. Клинико-гемодинамическая эффективность триметазидина в комплексной терапии ранней постинфарктной стенокардии. Клин. фармакология и терапия. 1996; 3: 17–20.
17. Колычева С.В., Ходарева Е.Н., Жарова Е.А. Клинико-инструментальная оценка эффективности предуктала у больных ИБС. Практикующий врач. 1999; 15.
18. Жарова Е.А., Лепахин В.К., Фитилев С.Б. и др. Триметазидин в комбинированной терапии стенокардии напряжения (ТАСЕ – Effect of Trimetazidine in patients with stable effort Angina in Combination with existing Therapy). Сердце. 2002; 1 (4): 204–7.
19. Belardinelly R. Trimetazidine and the contractile response of dysfunctional myocardium in ischemic cardiomyopathy. Rev Port Cаrdiol 2000; 19 (5): 35–9.
20. Lu C, Dabrovski P, Fragasso G et al. Effect of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898–901.
21. Сhierchia SL, Fragasso G. Protective effects of trimetazidine on ischaemic dysfunction. Eur Heart J 1999; 1: 24–7.
22. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161–5.
23. Vitale C, Wajngaten M, Sposato B et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814–21.
24. Kantor P, Lucien A, Kozak R, Lopaschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial Long-Chain 3-Ketoacyl-Coenzym A Thiolase. Circ Res 2000; 86: 580–8.
25. Brottier L, Barat JL, Combe C et al. Theraputic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207–12.
26. Бузиашвили Ю.И., Маколкин В.И., Осадчий К.К. и др. Влияние триметазидина на обратимую дисфункцию миокарда при ишемической болезни сердца. Кардиология. 1999; 39 (6): 33–8.
27. Терещенко С.Н., Акимова О.С., Демидова И.В. и др. Цитопротектор триметазидин в комплексной терапии тяжелой постинфарктной хронической сердечной недостаточности. Кардиология. 1999; 9: 48–52.
28. Fragasso G, Rosano G, Baek SH et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. Int J Cardiol 2012. Pii: S0167-5273(12)01244-2. Doi: 10.1016/j.ijcard.2012.09.123
29. Lei Zhang, Yizhou Lu, Hong Jiang et al. Additional Use of Trimetazidine in Patients With Chronic Heart Failure. J Am Coll Cardiol 2012; 59 (10): 913–22.
30. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161–5.
31. Fragasso G, Perseghin G, De Cobelli F et al. Effects of metabolic modulation by trimetazidine on left ventricular function an phosphocreatine/adenosine triphopshate ratio in patients with heart failure. Eur Heart J 2006; 27: 942–8.
32. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26L–40L.
33. Bristow MR, Gilbert EM. Improvement of cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J 1995; 16 (Suppl. F): 20–31.
34. CIBIS Investigators and Committees. A randomized trial b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–73.
35. Eichhorn EJ, Heesch CM, Barnett JH et al. Effects of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310–20.
36. Packer M, Bristow MR, Cohn JN et al for the US Carvedilol Heart Failure Study Group. Effects of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996; 334: 1349–55.
37. Waagstein F, Bristow MR, Swedberg K et al for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6.
38. Агеев Ф.Т. Влияние современных медикаментозных средств на течение заболевания, качество жизни и прогноз больных с различными стадиями хронической сердечной недостаточности. Дисс. ... д-ра мед. наук. 1997.
39. Агеев Ф.Т., Мареев В.Ю. Лопатин Ю.М., Беленков Ю.Н. Роль различных клинических, гемодинамических и нейрогуморальных факторов в определении тяжести хронической сердечной недостаточности. Кардиология. 1995; 11: 4–11.
40. Ахмедярова Н.К. Неинвазивная оценка миокардиального резерва и состояния диастолической функции у больных ИБС с обратимой дисфункцией миокарда по данным стресс-эхокардиографии с добутамином. Дисс. ... канд. мед. наук. 2000.
41. Lu C, Dabrowski P, Fragasso G, Chierchia S. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898–901.

Т.А.Федорова, Ю.В.Ильина, М.К.Рыбакова, И.А.Максимова

Кафедра терапии факультета послевузовского профессионального образования врачей ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ